Artwork for podcast Let’s Talk Medtech
Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care
Episode 381st April 2022 • Let’s Talk Medtech • Informa Markets
00:00:00 00:24:04

Share Episode

Shownotes

Embecta is now fully independent from Becton Dickinson & Co. Devdatt Kurdikar, Embecta's CEO talks about what that means going forward and his plans for the company.  With its rich pedigree and newly-independent status, Embecta is truly the new/old kid on the block in diabetes care.

Follow

Links